813-74-1

Usage

Safety Profile

A poison by ingestion.Moderately toxic by inhalation. When heated todecomposition it emits toxic vapors of NOx and Clí.

InChI:InChI=1/C3H2Cl3N/c4-1-3(5,6)2-7/h1H2

Upstream product

• 542-76-7 3-Chloropropionitrile 
• 107-13-1 acrylonitrile 
• 920-37-6 2-Chloroacrylonitrile 
• 10151-09-4 (1,1,2,2,3-pentachloro-propyl)-phosphorimidic acid trichloride 
• 7782-50-5 chlorine 
• 875231-35-9 2,3,3-trichloro-propionitrile 

Downstream Products

• 3278-46-4 chloropon 
• 13601-94-0 2,2,3-trichloro-propionic acid amide 
• 920-37-6 2-Chloroacrylonitrile 
• 93140-66-0 phenyl-bis-(2,2,3-trichloro-propionylamino)-methane 
• 6066-06-4 β.β.γ-Trichlor-propylamin 
• 2601-89-0 2,3-dichloropropionitrile 
• 22410-58-8 2,3-dichloroacrylonitrile 
• 554-68-7 triethylamine hydrochloride 

Relevant academic research and scientific papers

Alpha-halo-β-(substituted)thioacrylonitriles and their use for inhibiting the growth of microorganisms

Userful as antimicrobial agents in aqeuous systems are α-haloβ-(substituted)thioacrylonitriles of the formula STR1 wherein X represents Cl, Br or I and R represents a lower alkyl, aryl, aralkyl, heterocyclo, or a thiocarbonyl group. The configuration about the double bond may be E or Z or a mixture thereof. These compounds provide effective control of microbial growth. The derivatives of formula I are economically prepared from acrylonitrile via a three-step process involving (a) halogenation, (b) dehydrohalogenation and (c) nucleophilic-type displacement. Except for those compounds wherein X is bromo and R is methyl or phenyl, the compounds of formula I are not mentioned in the prior art.

CONDENSED DIAZEPINONES, THEIR COMPOSITIONS AND METHODS OF USE AS PHARMACEUTICALS

Disclosed are novel condensed diazepinones of formula I STR1 wherein B is a fused ring selected from STR2 X is--CH--or, when B is ortho-phenylene, X can also be nitrogen; A 1 is C 1-C. sub.2 alkylene; A 2 is C 1-C 2 when it is in the 2-position relative to the saturated heterocyclic ring nitrogen or a single bond or methylene when it is in the 3-or 4-position; R 1 is C 1-C 3 alkyl; R 2 is C. sub.1-C 7 alkyl, optionally hydroxy-substituted on at least one of its second to seventh carbon, or C 3-C 7 cycloalkyl, optionally hydroxy substituted, or C 3-C 7 cycloalkylmethyl; or R 1 and R 2 can, together with the nitrogen therebetween, be a 4-to 7-membered saturated monocyclic, heterocyclic ring which can optionally include an oxygen or N--CH 3 ; R 3 is hydrogen, chlorine, or methyl; R 4 is hydrogen or C 1-C 4 alkyl, R 5 is hydrogen, chlorine or C 1-C 4 alkyl; and Z is a single bond, oxygen, methylene or 1,2-ethylene; and NR 1 R 2--N oxides and nontoxic, pharmaceutically acceptable addition salts thereof. Also disclosed are pyrrolobenzodiazepinone intermediates, pharmaceutical compositions containing the condensed diazepinones and methods of using them to treat cardiovascular disorders, particularly bradycardia and bradyarrhythmia.